New 2022 ADA/EASD Guidelines: GLPP-1 RA/Insulin Combination Is Recommended

ADA/EASD recommend considering combination injectables therapy of basal insulin/GLP-1 RA (Such as Soliqua^®) as valuable treatment option to provide adequate efficacy for achieving and maintaining glycemic goals.

SOLIQUA^®, a combination of basal insulin and GLP-1 receptor agonists, has been jointly recommended by the ADA and EASD as an effective strategy for achieving and maintaining glycemic control in type 2 diabetes.

SOLIQUA^® distinguishes itself from intensified insulin regimens by offering robust glucose-lowering benefits while minimizing weight gain and reducing the risk of hypoglycemia. Furthermore, SOLIQUA^® streamlines the administration of insulin regimens, providing individuals with an easier and more efficient approach to diabetes management.